- Home
- DNP vs PCVX Comparison
DNP vs PCVX Comparison
Compare DNP & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DNP | PCVX |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 6.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | DNP | PCVX |
|---|---|---|
| Price | $10.05 | $46.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $101.67 |
| AVG Volume (30 Days) | 479.6K | ★ 1.5M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.30 | N/A |
| Revenue | ★ $154,887,179.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.26 | ★ N/A |
| Revenue Growth | ★ 3.30 | N/A |
| 52 Week Low | $8.69 | $27.66 |
| 52 Week High | $10.04 | $94.60 |
Technical Indicators
Market Signals| Indicator | DNP | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 46.06 | 51.97 |
| Support Level | $10.00 | $43.78 |
| Resistance Level | $10.35 | $48.11 |
| Average True Range (ATR) | 0.11 | 1.99 |
| MACD | -0.02 | -0.49 |
| Stochastic Oscillator | 14.29 | 42.99 |
Price Performance
Historical ComparisonAbout DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.